RESUMO

This study aimed to evaluate humoral responses after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) of patients with inflammatory bowel disease (IBD). Patients with IBD enrolled in a tertiary outpatient unit were followed up between September 2021 and September 2022 via serial blood collection. Immunoglobulin G antibody titers against SARS-CoV-2 were measured before administration and 1 and 6 months after the administration of two doses of different vaccination regimens. The results were compared with those of a healthy control group obtained during the same period. The mean pre-vaccination antibody titers were 452.0 and 93.3 AU/mL in the IBD (n = 42) and control (n = 89) groups, respectively. After two doses of the vaccine, the titers significantly increased in both groups (IBD, 8568.0 AU/mL; control, 7471.0 AU/mL; p < 0.001). One month after the second dose, no significant differences were observed between the two groups (p = 0.955). Significant differences between vaccination schemes in the IBD group were observed, with higher titers in those who received Pfizer, younger patients (p < 0.005), and those with a previous coronavirus disease 2019 (COVID-19) infection (p < 0.012). The use of immunosuppressants and immunobiologicals did not affect the overall humoral response to COVID-19 vaccine in patients with IBD, but specific vaccine regimens, age, and previous coronavirus infection significantly did. This study reinforces the positive impact of booster doses and the safety of SARS-CoV-2 vaccination.

RESUMO

BACKGROUND: Convalescent plasma (CP) became a prominent treatment in the early stages of the SARS-CoV-2 pandemic. In Argentina, a randomized clinical trial was executed to compare the use of CP in inpatients with severe COVID-19 pneumonia versus placebo. No differences in clinical outcomes or overall mortality between groups were observed. We conducted a cohort study in outpatients enrolled in the trial to describe long-term antibody titer variations between CP and placebo recipients. METHODS: Patients' total SARS-CoV-2 IgG antibodies against spike protein were collected 3, 6 and 12 months after hospital discharge from August 2020 to December 2021. In addition, reinfections, deaths and vaccination status were retrieved. Statistical analysis was performed using antibody geometric mean titers (GMT). All estimations were made considering the date of the trial infusion (placebo or CP) as time 0. RESULTS: From the 93 patients included in the follow-up, 64 had received CP and 29 placebo. We excluded all 12-month measurements because they were collected after the patients' vaccination date. At 90 days post-infusion, patients had an antibody GMT of 8.1 (IQR 7.4-8.1) in the CP group and 8.8 (IQR 8.1-9.1) in the placebo group. At 180 days, both groups had a GMT of 8.1 (IQR 7.4-8.1). No statistical differences in GMT were found between CP and placebo groups at 90 days (p = 0.12) and 180 days (p = 0.25). No patients registered a new COVID-19 infection; one died in the CP group from an ischemic stroke. CONCLUSIONS: No differences were observed in long-term antibody titers in unvaccinated patients that received CP or placebo after severe COVID-19 pneumonia.

Assuntos

RESUMO

Background: COVID-19 vaccines that trigger a strong secretory antibody response in breast milk may achieve effective passive protection of vulnerable newborns and breastfed infants of immunized mothers. The aim of this work was to investigate the presence of SARS-CoV-2 spike RBD-specific IgA and IgG antibodies in breast milk, 5 and 9 weeks after vaccination with 3 doses of the protein subunit vaccine Abdala, compared to those found in breast milk from COVID-19-recovered women, collected at least 40 days after the infection. Methods: SARS-CoV-2 spike RBD-specific IgA and IgG antibodies were semi-quantified by indirect ELISA, using a homemade standard generated by pooling twenty breast milk samples with high absorbance values according to preliminary data. The validity of the standard curves was proved following the European Medicines Agency Guideline. Two breast milk samples from 2 unvaccinated women who had not been infected with COVID-19 were included as negative controls. Potentially neutralizing antibodies was assessed by a SARS-CoV-2 surrogate virus neutralization test. Results: High levels of anti-RBD IgA antibodies were detected in breast milk samples 9 weeks after vaccination and anti-RBD IgG antibodies rise from the fifth to the ninth week. In the post-COVID-19 time that was evaluated, the IgG-type response was notably higher compared to both post-vaccination periods. Neutralizing antibody titers were similar in breast milk from vaccinated and COVID-19 recovered women. Conclusions: This is the first report about the immune response in breast milk after the administration of a COVID-19 protein subunit vaccine, which could provide analogous protection to that conferred by SARS-CoV-2 infection. This implies a potential passive immunity that breastfed infants receive from their mothers vaccinated with Abdala.

RESUMO

Critical antibody titers have been described as factors associated with hemolysis in ABO plasma-incompatible platelet (PLT) transfusions. This study was carried out to describe the frequency of high-titers anti-A and antiB IgM and IgG antibodies in group O apheresis platelet donors, and to explore differences according to the donor characteristics. A cross-sectional study was carried out at the Blood Bank of a National Hospital in Peru from January to March 2019. IgM and IgG antibodies against A1 and B antigens were quantified in 339 platelet donors using the direct hemagglutination technique and the solid-phase adherence technique, respectively. For analysis purposes, two cut-off points; ≥128 and ≥64, were used to define a critical titer for IgM due to a lack of consensus. An IgG titer of ≥256 was also defined as critical. Of the donors, 22.1 % had critical IgM titers when the cut-off point was defined as ≥128. However, when the IgM cut-off was ≥64, the frequency of platelet donors with critical titers increased to 54.0 %. The frequency of donors with critical IgG titers was 23.5 %. Higher IgG titers were associated with female donors while higher IgM titers were negative associated with age. One in two or three platelet donors, depending on the cutoff point used to define a critical IgM titer, had at least one critical titer of anti-A or anti-B antibodies. Early identification of platelet donors with critical antibody titers could prevent passive transfusion of ABO antibodies to non-isogroup recipients.

Assuntos

RESUMO

Cane toads (Rhinella marina) were introduced worldwide and have become invasive in multiple locations, representing a major driver of biodiversity loss through competition (food, shelter, territory), predation, and the poisoning of native species. These toads have been used in Australia as a model for studies concerning invasion biology and ecoimmunology, as longer-established (core) and invasion front (edge) populations show altered stress and immune response profiles. Although cane toads were also introduced into the United States in the 1950s, these patterns have yet to be evaluated for the populations spanning Florida. Toads introduced into Florida have dispersed primarily northward along a latitudinal gradient, where they encounter cooler temperatures that may further impact stress and immune differences between core and edge populations. In this study, we sampled cane toads from nine different locations spanning their invasion in Florida. Cane toads from southern populations showed higher plasma bacterial killing ability and natural antibody titers than the toads from the northern populations, indicating they have a better immune surveillance system. Also, southern toads were more responsive to a novel stressor (1 hr restraint), showing a higher increase in corticosterone levels. These results indicate that possible trade-offs have occurred between immune and stress responses as these toads have become established in northern cooler areas in Florida.

Assuntos

RESUMO

The clinical effects and immunological response to the influenza vaccine in women who later become pregnant remain to be thoroughly studied. Here, we report the medical outcomes of 40 women volunteers who became pregnant after vaccination with an experimental virus-like particle (VLP) vaccine against pandemic influenza A(H1N1)2009 (influenza A(H1N1)pdm09) and their infants. When included in the VLP vaccine trial, none of the women were pregnant and were randomly assigned to one of the following groups: (1) placebo, (2) 15 µg dose of VLP vaccine, or (3) 45 µg dose of VLP vaccine. These 40 women reported becoming pregnant during the follow-up phase after receiving the placebo or VLP vaccine. Women were monitored throughout pregnancy and their infants were monitored until one year after birth. Antibody titers against VLP were measured in the mothers and infants at delivery and at six months and one year after birth. The incidence of preeclampsia, fetal death, preterm delivery, and premature rupture of membranes was similar among groups. All vaccinated women and their infants elicited antibody titers (≥1:40). Women vaccinated prior to pregnancy had no adverse events that were different from the nonvaccinated population. Even though this study is limited by the sample size, the results suggest that the anti-influenza A(H1N1)pdm09 VLP experimental vaccine applied before pregnancy is safe for both mothers and their infants.

Assuntos

RESUMO

The current study was conducted to examine the effects of an herbal compound, a probiotic and an antibiotic growth promoter (AGP) on the performance, intestinal bacterial population, antibody titers, and morphology of the jejunum and ileum of broilers. A number of 240 male Ross 308 broilers were distributed into four treatments, with five replicates of 12 bird each. The experimental period was 42 days. Treatments includes: 1) basal diet; 2) basal diet supplemented with an AGP (phospho-flavomycin at 450 mg/kg of diet); 3) basal diet supplemented with a Lactobacillus-containing probiotic (250 mg/kg of diet); and 4) basal diet supplemented with an herbal compound (containing thyme, oregano, chamomile, and peppermint essential oils at 1 g/kg of diet). Body weight (BW) and cumulative feed intake (CFI) were measured weekly. Blood parameters, intestinal morphology, vaccine immunity titers, and intestinal microbial population were measured on day 42. The results showed that probiotic and herbal compound supplementation significantly increased body weight (BW) and decreased feed conversion ratio (FCR) (p<0.05), in comparison with the basal diet. A significant increase in vaccine titers against Avian Influenza, Newcastle disease, and Infectious Bursal Disease were achieved with the treatment with herbal compound supplementation. Herbal compound significantly reduced triglycerides, cholesterol, LDL concentration and ALP, AST and ALT activities and increased the HDL levels in blood serum of chicks (p<0.05). The bacterial load of E. coli, Salmonella and coliforms of the AGP-fed group was significantly lower than those fed the control diet. Significant increases in villus height and decrease in crypt depth and goblet cells were seen in the ileum and jejunum of probiotic-fed broilers (p<0.05). In conclusion, better overall immune status and blood biochemical parameters were obtained with the herbal compound than with the probiotic; however, the performance of...(AU)

Assuntos

RESUMO

The current study was conducted to examine the effects of an herbal compound, a probiotic and an antibiotic growth promoter (AGP) on the performance, intestinal bacterial population, antibody titers, and morphology of the jejunum and ileum of broilers. A number of 240 male Ross 308 broilers were distributed into four treatments, with five replicates of 12 bird each. The experimental period was 42 days. Treatments includes: 1) basal diet; 2) basal diet supplemented with an AGP (phospho-flavomycin at 450 mg/kg of diet); 3) basal diet supplemented with a Lactobacillus-containing probiotic (250 mg/kg of diet); and 4) basal diet supplemented with an herbal compound (containing thyme, oregano, chamomile, and peppermint essential oils at 1 g/kg of diet). Body weight (BW) and cumulative feed intake (CFI) were measured weekly. Blood parameters, intestinal morphology, vaccine immunity titers, and intestinal microbial population were measured on day 42. The results showed that probiotic and herbal compound supplementation significantly increased body weight (BW) and decreased feed conversion ratio (FCR) (p<0.05), in comparison with the basal diet. A significant increase in vaccine titers against Avian Influenza, Newcastle disease, and Infectious Bursal Disease were achieved with the treatment with herbal compound supplementation. Herbal compound significantly reduced triglycerides, cholesterol, LDL concentration and ALP, AST and ALT activities and increased the HDL levels in blood serum of chicks (p<0.05). The bacterial load of E. coli, Salmonella and coliforms of the AGP-fed group was significantly lower than those fed the control diet. Significant increases in villus height and decrease in crypt depth and goblet cells were seen in the ileum and jejunum of probiotic-fed broilers (p<0.05). In conclusion, better overall immune status and blood biochemical parameters were obtained with the herbal compound than with the probiotic; however, the performance of...

Assuntos

RESUMO

The aim of this study was to evaluate the effects of in-ovo vaccination on different incubation days of broiler embryos derived from young and old breeders on incubation indexes, vaccine response, and broiler performance. A number of 20,160 fertile eggs was distributed according to a completely randomized design in a 4 x 2 factorial arrangement (in-ovo vaccination on 16, 17, 18, or 19 days of incubation, and breeders of 31 or 52 weeks of age), totaling eight treatments with 15 replicates of 168 eggs each. Vaccination procedures and vaccines (strains and doses) were those routinely applied in commercial hatcheries. After hatch, 960 male chicks were housed and distributed according to the same experimental design previously applied in the hatchery. There were hatching losses (p < 0.05) when eggs were vaccinated before 18 days of incubation. Greater Marek's disease antibody titers were obtained when the in-ovo vaccination was performed on day 19 of incubation, regardless breeder age. Embryonic age at vaccination did not compromise broiler performance in the field, and the flexibility of embryonic age for in-ovo vaccination can reduces incubation costs.

Assuntos

RESUMO

The aim of this study was to evaluate the effects of in-ovo vaccination on different incubation days of broiler embryos derived from young and old breeders on incubation indexes, vaccine response, and broiler performance. A number of 20,160 fertile eggs was distributed according to a completely randomized design in a 4 x 2 factorial arrangement (in-ovo vaccination on 16, 17, 18, or 19 days of incubation, and breeders of 31 or 52 weeks of age), totaling eight treatments with 15 replicates of 168 eggs each. Vaccination procedures and vaccines (strains and doses) were those routinely applied in commercial hatcheries. After hatch, 960 male chicks were housed and distributed according to the same experimental design previously applied in the hatchery. There were hatching losses (p < 0.05) when eggs were vaccinated before 18 days of incubation. Greater Marek's disease antibody titers were obtained when the in-ovo vaccination was performed on day 19 of incubation, regardless breeder age. Embryonic age at vaccination did not compromise broiler performance in the field, and the flexibility of embryonic age for in-ovo vaccination can reduces incubation costs.(AU)

Assuntos